Which prognostic marker is responsible for the clinical heterogeneity in CLL with 13q deletion?
13q deletions
B-CLL
FISH
Prognostic marker
RB1 deletions
Journal
Molecular cytogenetics
ISSN: 1755-8166
Titre abrégé: Mol Cytogenet
Pays: England
ID NLM: 101317942
Informations de publication
Date de publication:
06 Jan 2021
06 Jan 2021
Historique:
received:
08
10
2020
accepted:
09
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it is observed the clinical course of CLL cases with del(13q) are quite heterogeneous and the responsible for this clinical heterogeneity has not been established yet. Some investigators suggest type II deletion (include RB1 gene) is associated with more aggressive clinical course. Also, it is suggested that the deletion burden and the deletion type have a prognostic effect. In this study, we aimed to investigate the effect of RB1 gene deletion, deletion burden and deletion type on overall survival (OS), disease stage and time to first treatment (TTFT) in patients with isolated del(3q). Sixty eight cases, detected isolated del(13q) were included in the study. Also, RB1 deletion was analyzed from peripheral blood of them using FISH. RB1 deletion was detected in 41% of patients, but there was no statistically significant difference between RB1 deletion and TTFT, stage and OS (p > 0.05). At same time, statistically significant difference was detected between high del(13q) (> 80%) and TTFT (p < 0.05). The statistical analysis of our data regarding to the association between RB1 deletion and deletion type, TTFT, disease stage, and OS has not confirmed type II deletion or biallelic deletion cause poor prognosis. However, our data supports the deletion burden has a prognostic effect. More studies are needed to elucidate the cause of the clinical heterogeneity of CLL cases with del(13q).
Sections du résumé
BACKGROUND
BACKGROUND
Deletion of 13q14 [del(13q)] is the most common cytogenetic change (50%) in chronic lymphoblastic leukemia (CLL), and it is a good prognostic factor if it is detected as a sole aberration by FISH. However, it is observed the clinical course of CLL cases with del(13q) are quite heterogeneous and the responsible for this clinical heterogeneity has not been established yet. Some investigators suggest type II deletion (include RB1 gene) is associated with more aggressive clinical course. Also, it is suggested that the deletion burden and the deletion type have a prognostic effect. In this study, we aimed to investigate the effect of RB1 gene deletion, deletion burden and deletion type on overall survival (OS), disease stage and time to first treatment (TTFT) in patients with isolated del(3q). Sixty eight cases, detected isolated del(13q) were included in the study. Also, RB1 deletion was analyzed from peripheral blood of them using FISH.
RESULTS
RESULTS
RB1 deletion was detected in 41% of patients, but there was no statistically significant difference between RB1 deletion and TTFT, stage and OS (p > 0.05). At same time, statistically significant difference was detected between high del(13q) (> 80%) and TTFT (p < 0.05).
CONCLUSION
CONCLUSIONS
The statistical analysis of our data regarding to the association between RB1 deletion and deletion type, TTFT, disease stage, and OS has not confirmed type II deletion or biallelic deletion cause poor prognosis. However, our data supports the deletion burden has a prognostic effect. More studies are needed to elucidate the cause of the clinical heterogeneity of CLL cases with del(13q).
Identifiants
pubmed: 33407772
doi: 10.1186/s13039-020-00522-1
pii: 10.1186/s13039-020-00522-1
pmc: PMC7788884
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Références
Leuk Lymphoma. 2014 Apr;55(4):920-8
pubmed: 24047479
Genes Chromosomes Cancer. 2011 Aug;50(8):633-43
pubmed: 21563234
N Engl J Med. 2000 Dec 28;343(26):1910-6
pubmed: 11136261
Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):249-256
pubmed: 29477297
Nat Rev Clin Oncol. 2019 Nov;16(11):684-701
pubmed: 31278397
Cancer Genet Cytogenet. 2009 Jan 15;188(2):65-9
pubmed: 19100507
J Mol Diagn. 2009 Jul;11(4):298-305
pubmed: 19460942
Clin Cancer Res. 2010 Dec 1;16(23):5641-53
pubmed: 20947517
Ann Hematol. 2018 Sep;97(9):1663-1669
pubmed: 29736587
Mol Cytogenet. 2016 Jan 06;9:1
pubmed: 26740820
Leukemia. 2011 Mar;25(3):489-97
pubmed: 21151023
Br J Haematol. 2013 Oct;163(1):47-54
pubmed: 23869550
Hematol Oncol. 2013 Sep;31(3):136-42
pubmed: 23060227
Mol Cytogenet. 2014 Nov 19;7(1):79
pubmed: 25435911
Cancer Res. 2008 Feb 15;68(4):1012-21
pubmed: 18281475
Hematol Oncol. 2012 Mar;30(1):46-9
pubmed: 21671253
J Clin Oncol. 2006 Oct 1;24(28):4634-41
pubmed: 17008705
Genes Chromosomes Cancer. 2016 Jan;55(1):16-24
pubmed: 26391112
Cancer. 2012 Jul 15;118(14):3531-7
pubmed: 22139735
Br J Haematol. 2010 Feb;148(4):544-50
pubmed: 19895615
Haematologica. 2009 Mar;94(3):364-71
pubmed: 19252174
Nat Rev Cancer. 2008 Sep;8(9):714-24
pubmed: 19143056
Clin Cancer Res. 2011 Nov 1;17(21):6778-90
pubmed: 21890456
Eur J Haematol. 2008 Aug;81(2):94-9
pubmed: 18462257
PLoS One. 2012;7(11):e48485
pubmed: 23152777